×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Are You Looking for a Top Momentum Pick? Why Context Therapeutics Inc. (CNTX) is a Great Choice
Yahoo Finance AU
Does Context Therapeutics Inc. (CNTX) have what it takes to be a top stock pick for momentum investors? Let's find out.
6 days ago
Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76
GlobeNewswire
CTIM-76 Phase 1 clinical trial to focus on CLDN6-positive gynecologic and testicular cancers Company expects to enroll first patient in...
3 weeks ago
Lowenstein Represents Piper Sandler in Private Placement of $100M Common Stock of Context Therapeutics Inc.
Lowenstein Sandler LLP
Lowenstein Sandler represented leading investment bank Piper Sandler (NYSE: PIPR) in its role as sole placement agent for the private...
3 weeks ago
Context Therapeutics Inc. (CNTX) Upgraded to Buy: Here's Why
Zacks Investment Research
Context Therapeutics Inc. (CNTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a...
2 weeks ago
Context Therapeutics files IND application for CTIM-76 for CLDN6-positive gynecologic and testicular cancers
BioWorld MedTech
Context Therapeutics Inc. has submitted an IND application to the FDA to begin a first-in-human phase I study of CTIM-76 in patients with...
1 month ago
Context Therapeutics Secures Funding, Advances Clinical Trials - TipRanks.com
Tipranks
The latest announcement is out from Context Therapeutics (CNTX). Context Therapeutics Inc. has initiated a private placement deal to raise approximately...
3 weeks ago
Context Therapeutics Reports Full Year 2023 Operating and Financial Results
Yahoo Finance
CTIM-76 IND filing on track for late March 2024 Cash and cash equivalents of $14.4 million as of December 31, 2023 Company expects its cash...
2 months ago
Context Therapeutics Posts Strong Q1 Financials, Advances Key Cancer Drug Trials
MyChesCo
PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX), a pioneering biopharmaceutical company, unveiled its first-quarter financial...
2 weeks ago
Context Therapeutics Reports First Quarter 2024 Operating and Financial Results
GlobeNewswire
Announced FDA clearance of IND application for a Phase 1 clinical trial of CTIM-76 Completed $100 million financing; expected to extend...
2 weeks ago
Context Therapeutics gets FDA approval for clinical trials of cancer drug - Pennsylvania Business Report
Pennsylvania Business Report -
On Thursday, Philadelphia-based Context Therapeutics, Inc. announced it had received clearance from the U.S. Food and Drug Administration (FDA) to begin...
3 weeks ago